LiDORx®, formulated and manufactured by Gensco in a FDA licensed facility, contains 3% lidocaine hydrochloride (30mg of lidocaine HCl in each gram of gel) in a patented transdermal delivery system. The transdermal delivery system enhances the absorption of the lidocaine across the skin barrier yielding a much greater effect (topical anesthesia) than other prescription formulations including those containing 5% Lidocaine as clinically proven by the LiDORx Activation Study.
Indications for Use:
Indicated as an anesthetic for:
- Relief of pain at site of injury
- Relief of musculoskeletal pain and soreness
- Pain from neuropathy
- Local medical procedures; injections and vaccines
- Relief of pruritis, pruritic eczema, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritis ani, pruritis vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes
LiDORx® is an effective topical anesthetic best used for minor to moderate pain relief. LiDORx® can be applied as needed over 24-hours unlike the patch system that must be removed after 12 hours.
LiDORx® Size 10mL NDC 35781-0300-1 0.33 fl oz. (10mL) equivalent to 40 doses. Apply 1-4 pumps QID over 24-hour period or as directed by a physician. Maximum 16 pumps over 24 hours.
LiDORx® Size 30mL NDC 35781-0300-3 1.01 fl oz. (30mL) equivalent to 120 doses. Apply 1-4 pumps QID over 24-hour period or as directed by a physician. Maximum 16 pumps over 24 hours.
LiDORx® Size 90mL NDC 35781-0300-9 3.04 fl oz. (90mL) equivalent to 360 doses. Apply 1-4 pumps QID over 24-hour period or as directed by a physician. Maximum 16 pumps over 24 hours.
Lidocaine HCl Transdermal Gel for Rapid Anesthesia and Site-Specific Relief of Pain
Onset of action as fast as 5 minutes.
LiDORx® provides topical non-narcotic temporary relief for pain as prescribed by a physician. LiDORx® (Lidocaine HCl USP 3%) applied in controlled doses provide relief of surface pain and utilizes MDose™ Technology which dispenses the exact amount of medication (0.25 ml per pump) per application. LiDORx® is only available by prescription.
LiDORx® contains lidocaine hydrochloride formulated into a patented transdermal gel that is designed to enhance the penetration of lidocaine HCl through the skin into the affected tissues. Since LiDORx® is not a patch, it can be applied in varying amounts, within package insert guidelines, to even difficult areas including joints, back, neck, legs, and arms regardless of bony protuberances or motion. In addition, peripheral neuropathies have been shown to benefit from topical lidocaine application.
- Launched March 2013
- Available by prescription only
- Odorless, colorless gel
- Non-Narcotic and Non-Addictive
- Gensco’s unique metered dose technology (MDose™) dispenses the exact amount of medication (0.25 mL per pump) per application which covers a 2″x2″ area of skin
All Gensco products, including LiDORx®, are distributed to pharmacy chains such as Walgreens®, CVS®, Walmart®, RiteAid®, Kroger® and Publix® through the major wholesalers such as McKesson, Cardinal and AmerisourceBergen. LiDORx® is contracted with DAPA (Contract #SP0200-15-H-0003), Federal Supply Schedule (FSS), making it accessible to all military personnel and is also available to all MEDICARE patients (Medicare Contract #P1466). LiDORx® is available through these Group Purchasing Organizations (GPOs): Intalere, Innovatix, MedAssets, Premier, MHA, ROi and Vizient.
Gensco sponsored internal testing has demonstrated a greater degree of drug movement across synthetic human skin (in vitro diffusion cell tests), estimated at more than 3 times that of typical topical lidocaine formulations. more…
- Skin Tears Treatment Market to Observe Strong Development by 2018-2026 April 15, 2019 Articles, Featured, Industry - [To download a printable version of this article, click here] MARKET RESEARCH April 12, 2019… more...
- Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAPORT® (Rizatriptin Oral Film) in the United States December 12, 2018 Featured, Industry, Press Release, Product Update - Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in… more...
- AAP Issues Flu Vaccine Recommendations for 2018-2019 September 6, 2018 Articles, Industry - All children should receive the flu shot as soon as it is available: AAP [To… more...
- A Case Study of Treatment of Recalcitrant Nonpressure Chronic Ulcers Using Astero Gel Topical Hydrogel with 4% Lidocaine for Autolytic Debridement and Pain Management November 13, 2017 Articles, Clinical, Featured, Research - more...